The Pharmamar biopharmaceutics remains one of the companies with the greatest remuneration to the shareholder, for the sixth consecutive year. The Board of Directors of the firm has proposed this Wednesday raise the profitability of its dividend to an amount of 0.80 euros for each title in circulationaccording to a statement sent to the National Securities Market Commission (CNMV). This cast, which will be equivalent to a disbursement of 14.57 millionit is an interannual 23% increase to the last dividend paid for 0.65 euros per share.
This decision, which the company has justified based on its solid financial results in the last year, arrives just a few weeks after the launch of a new program of shares to increase 0.5% of its share capital. The pharmaceutical company increased its income by 11% with respect to the previous year, until it touching 174.9 million euros. In other words, the benefit shot at 2,270% in 2024until touching 26.1 million euros, while the net box stood at 109 million euros.
«This proposal of the Pharmamar Board of Directors involves distributing dividend for the sixth consecutive year, throughout this period the company has distributed dividends for a total accumulated amount of more than more than 70 million euros»The company communicated this Wednesday.
Despite this announcement, Pharmamar’s titles have started the stock market quoting down, and they are left to 1.5% in the stock market. In the last month, Pharmamar titles in the stock market have sunk around 10%. However, in the last six months, Pharmamar’s rise in the Spanish Stock Exchange has been dizzying: its titles have been revalued by 81%, and 211% in the last year.
The Madrid pharmacist has three drugs marketed among them, an advanced ovarian cancer treatment, another treatment of lung cancer and treatment for patients with multiple myeloma. The success of these medications has aroused interest in investment circles in recent years. For example, the investment bank, JP Morgan, which is among the first shareholders, recently raised their commitment to the company with a 3.12% participation in the capital. The dividend proposal will be submitted to approval at the next General Meeting of Shareholders in April.
